FILE:BSX/BSX-8K-20041220172614.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	Financial Statements and Exhibits
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM: Financial Statements and Exhibits
================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ________________ FORM 8-K ________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2004 BOSTON SCIENTIFIC CORPORATION -------------------------------------------------- (Exact name of registrant as specified in charter) DELAWARE 1-11083 04-2695240 --------------- ------------ ------------------- (State or other (Commission (IRS employer jurisdiction of file number) identification no.) incorporation) One Boston Scientific Place, Natick, Massachusetts 01760-1537 ------------------------------------------------------------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (508) 650-8000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions: [_] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ================================================================================
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On December 14, 2004, the Board of Directors of Boston Scientific Corporation (the "Company") appointed Paul A. LaViolette to the position of Chief Operating Officer of the Company. Prior to this appointment, Mr. LaViolette, 47, served as Senior Vice President and Group President for the Company's Cardiovascular businesses. Mr. LaViolette joined the Company in January 1994 as President of Boston Scientific International. In February 1995, he became Group President for the Company's Endoscopy and Urology businesses. In 1998, he again joined Boston Scientific International as its President to help strengthen and stabilize the organization. In 2000, Mr. LaViolette added Group President responsibilities for the Scimed, EP Technologies and Target divisions, and in 2001 also took on the role of President of Scimed. During 2000, the Company provided a home improvement loan in the amount of $400,000 to Mr. LaViolette. The principal balance on the loan bears interest at the then-current applicable federal rate for medium term notes (approximately 6%) until the principal balance is paid in full. Principal, together with interest compounded quarterly, is due and payable in October 2005. The Company announced additional management promotions. A copy of the press release is attached hereto as Exhibit 99.1. The Company also provides retention and indemnification agreements to its executive officers. Forms of these agreements have been previously filed by the Company with the Securities and Exchange Commission. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. 99.1 Press Release dated December 20, 2004
SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BOSTON SCIENTIFIC CORPORATION Date: December 20, 2004 By: /s/ Lawrence J. Knopf -------------------------- Lawrence J. Knopf Vice President and Assistant General Counsel
INDEX TO EXHIBITS EXHIBIT NUMBER DESCRIPTION - ------ ----------- 99.1 Press Release dated December 20, 2004

EXHIBIT 99.1 ------------ NEWS Boston FOR IMMEDIATE RELEASE Scientific Boston Scientific Corporation One Boston Scientific Place Natick, MA 01760-15337 508-650-8000 www.bostonscientific.com BOSTON SCIENTIFIC ANNOUNCES MANAGEMENT EXPANSION COMPANY STRENGTHENS MANAGEMENT TEAM FOR CONTINUED GROWTH AND SUCCESS PAUL LAVIOLETTE NAMED CHIEF OPERATING OFFICER Natick, MA (December 20, 2004) - Boston Scientific Corporation (NYSE: BSX) today announced an expansion of its management structure designed to position the Company for continued growth and success. The expansion includes the appointment of Paul LaViolette as Chief Operating Officer, as well as a number of other promotions. Paul has served in several positions since joining the Company in 1994. Most recently, he has served as Senior Vice President and Group President for Cardiovascular. He will now assume responsibility for all the Company's business units and worldwide commercial activities, with the exception of the recently acquired Advanced Bionics Corporation. Among his new responsibilities will be the Company's Endosurgery Group, which will continue to be managed by Steve Moreci, Senior Vice President and Group President for Endosurgery. Paul will also share responsibility for the Company's manufacturing activities, which will continue to report to Jim Taylor, Executive Vice President for Operations. In addition, Paul will share responsibility for research and development, which will continue to report to Fred Colen, Executive Vice President and Chief Technology Officer. Several current Company executives have been promoted and named to the Executive Committee. They are: o Brian Burns: Senior Vice President for Quality o Jeff Goodman: Senior Vice President, and President of International o Ken Pucel: Senior Vice President for Operations o Dr. Mary E. Russell: Senior Vice President for Clinical and Regulatory, and Chief Medical Officer As head of International, Jeff Goodman will oversee all business units and commercial activities -- more --
Boston Scientific Corporation/Page 2 December 20, 2004 outside the United States. The Company does business in approximately 100 countries, and International revenues in 2004 are expected to exceed $2 billion. Jeff joined the Company in 1999 and has served as President of Inter-Continental, which includes all countries outside the United States, Europe and Japan. During his tenure, Inter-Continental's revenues quintupled and profits increased dramatically. Dr. Mary Russell's responsibilities will increase significantly. She will now oversee all preclinical, clinical and regulatory affairs for the Company. Previously, she served as Senior Vice President and Chief Medical Officer for Cardiovascular Clinical Sciences. In that capacity, she led the planning and execution of the clinical strategy that led to the approval of the Company's TAXUS(TM) Express(2)(TM) paclitaxel-eluting coronary stent system. In addition, she developed a Company-wide clinical infrastructure to support global trial requirements. Dr. Russell assumes responsibility for regulatory affairs from Dennis Ocwieja, who is retiring from the Company. Jim Gilbert is joining the Company as a Senior Vice President and a member of the Executive Committee. He will be responsible for a broad portfolio, providing strategic support on key projects and growth initiatives. He will also manage Corporate E-Marketing, Corporate Marketing Science, Corporate Sales and National Accounts, and Reimbursement and Outcomes Planning. Jim is a veteran of 23 years at Bain and Company, where he served as a director and a partner, and was the managing partner of Bain's Global Healthcare Practice. Hank Kucheman has been promoted to President of the Company's Interventional Cardiology business. Hank has been with the Company since 1990, and he most recently served as Senior Vice President for Cardiovascular and Corporate Marketing. Several existing members of the Company's Executive Committee have been promoted. Their new titles are: o Larry Best: Executive Vice President for Finance and Administration, and Chief Financial Officer o Fred Colen: Executive Vice President and Chief Technology Officer o Paul Donovan: Senior Vice President for Corporate Communications o Bob MacLean: Executive Vice President for Human Resources o Paul Sandman: Executive Vice President, Secretary and General Counsel o Jim Taylor: Executive Vice President for Operations "Boston Scientific has enjoyed an extraordinary amount of growth and success over the past few years, due in large part to the management team I am recognizing with these promotions," said Jim Tobin, -- more --
Boston Scientific Corporation/Page 3 December 20, 2004 President and Chief Executive Officer of Boston Scientific. "These changes are designed to position the Company for future growth and sustained leadership over the long haul. All these people have proved themselves as talented and effective managers. I am confident their past achievements are solid indications of their future promise." This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be affected by the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com. CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation


